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I-1 OARSI AND NICE: ARE THEY BETTER THAN PREVIOUS
GUIDELINES?
G. Nuki1, R. Moskowitz2, W. Zhang3. 1University of Edinburgh,
Edinburgh, UNITED KINGDOM, 2Case Western Reserve University,
Cleveland, OH, USA, 3University of Nottingham, Nottingham, UNITED
KINGDOM
Purpose: In recent years guidelines for the treatment of osteoarthritis
(OA) have been criticised for lack of methodological rigour, stakeholder
involvement and applicability. The Osteoarthritis Research Society Inter-
national (OARSI) has recently published global evidence-based, expert-
consensus treatment guidelines for OA hip and knee [1,2]. The National
Institute for Health and Clinical Excellence (NICE) has also recently
published a National Clinical Guideline for the Care and Management
of OA in the National Health Service (NHS) in Great Britain [3]. The aim
of this study was to attempt to assess whether the OARSI and NICE
recommendations were any better than previous guidelines.
Methods: The quality of the guidelines was assessed using the AGREE
(Appraisal of Guidelines for Research and Evaluation) instrument and
standardised percent scores for scope, stakeholder involvement, rigour,
clarity, applicability and editorial independence, as well as overall qual-
ity were calculated. Assessments were undertaken by an international
panel of 7 independent experts from a variety of health professional
disciplines. Scores were also compared with AGREE appraisals of the
OARSI guidelines undertaken by 4 scientists from the American Academy
of Orthopaedic Surgeons (AAOS) and with the appraisals of the 23
previously published guidelines [2].
Results: Both OARSI and NICE guidelines had higher scores for each
domain of quality than previously published guidelines. The OARSI rec-
ommendations scored higher than the NICE guidelines for methodological
rigour (70% v 59%), editorial independence (75% v 48%) and overall
quality (58% v 50%), but had lower scores for stakeholder involvement
(42% v 49%), clarity (59% v 64%) and especially applicability (22% v
43%).
Conclusions: Appraisals of the OARSI and NICE guidelines suggest
that they are better in overall quality and in most quality domains than
previous guidelines. Nevertheless the quality of both could be signiﬁcantly
improved by wider stakeholder involvement and greater attention to
applicability. This is clearly a greater challenge for globally applicable
international guidelines than it is for a national guideline. The OARSI
guidelines can be adapted for national and regional application through
translation and liason with patients and professional groups representing
stakeholders in primary and secondary care worldwide [1].
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I-2 NEW EVIDENCE 2006–2008: WHAT IMPACT ON CURRENT
RECOMMENDATIONS?
W. Zhang1, R.W. Moskowitz2. 1Nottingham University, Nottingham,
UNITED KINGDOM, 2Case Western Reserve University, Beachwood,
OH, USA
Purpose: The Osteoarthritis Research Society International (OARSI)
developed global, evidence-based consensus treatment guidelines for
osteoarthritis (OA) of the hip and knee based on a systematic review
(SR) of the literature up to January 2006 [1,2]. Since then a large number
of new studies have been published. This study was designed to update
the evidence and to examine whether the more recent evidence would
inﬂuence the proﬁle of recommendations for core therapies for OA.
Methods: A systematic literature search was undertaken for new guide-
lines, SRs, randomised controlled trials (RCTs) and economic evaluations
(EEs) published between 31 January 2006 and 31 January 2008. The
quality of guidelines was appraised by an independent group of experts
and the core set of treatment modalities was determined by the level of
evidence and the frequency of recommendations. The quality of the RCTs
included in the SRs and of others retrieved from the literature search
were appraised, and where possible effect size (ES), number needed to
treat (NNT), relative risks (RR) or odds ratio (OR) and cost per quality
adjusted life years (QALY) gained were estimated. Statistical pooling was
undertaken as appropriate. Sensitivity analysis and cumulative meta-
analysis were conducted to examine the impact of studies published after
2006 and the stability of the effect.
Results: The literature search yielded 1347 citations in the last 2 years.
Of these 2 guidelines, 57 SRs, 200 RCTs and 16 EEs met inclusion
criteria. Core therapies, deﬁned as treatments supported by Ia level
evidence and a recommendation by all guidelines which addressed
that therapy, remained unchanged. These included exercise, education,
self-management, acetaminophen and COX-2 selective or non-selective
NSAIDs with PPI. Whilst the evidence for weight reduction was upgraded
from Ib to Ia, the frequency of recommendations for joint lavage was
reduced from 100% to 75%. ES changed with inclusion of additional trials.
For example the ES for pain relief was reduced from 0.21 (95%CI 0.02,
0.41) to 0.18 (0.04, 0.33) for acetaminophen, but was increased from 0.13
(−0.12, 0.38) to 0.20 (0.06, 0.33) for weight reduction. Cumulative meta-
analysis indicated stability of efﬁcacy for some therapies (eg, NSAIDs) but
not for others (eg, glucosamine and chondroitin sulphate). New treatment
modalities such as celecoxib plus PPI and Tai Chi exercise had been
assessed in RCTs. Cost per QALY had been estimated for behavioural
graded activity, class based exercise, unicompartment knee arthropathy,
and hip versus knee replacements.
Conclusions: Recent research evidence has resulted in changes in
the calculated risk-beneﬁt ratio for some treatments for osteoarthritis.
The rapid increase of new evidence presents challenges to guideline
developers. A regularly updated, evidence-based osteoarthritis research
database of well characterised trials of all modalities of treatment for OA
would be very useful.
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I-3 IS BEST AVAILABLE EVIDENCE THE BEST?
J.M. Bjordal1,2. 1Bergen University College, Bergen, NORWAY,
2University of Bergen, Bergen, NORWAY
Purpose: Evaluation of some of the pitfalls associated with comparisons
of the numerous interventions used in osteoarthritis management.
Methods: Literature review of systematic reviews and overviews with sen-
sitivity analysis of patient selection bias, interpretation of effect estimates,
level of evidence and strength of recommendation in osteoarthritis.
Results: Guidelines are often seen as the end results of a stringent
synthesis of the available literature. However, the picture of an unblem-
ished and rigorous scientiﬁc method for synthesizing scientiﬁc evidence
has been taking several blows lately. The method quality scoring of
randomized controlled trials (RCT) has proved less reliable than we hoped
for, and the interpretation of meta-analyses with mixed results seems
unreliable even among experienced reviewers. Methods for grading levels
of evidence are drifting from quantiﬁcation of a number of well-designed
RCTs or a single meta-analysis number to achieve the highest evidence
level, to qualitative evaluation of the likelihood for future change in
evidence. And recommendations are subject to a qualitative balancing
act of beneﬁt and harms. Guidelines can be seen as an anchor point
on a continuous line from (a) perfect consensus of experts on one side
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to, (b) the result of hard quantitative data on the other side. If we use
the perfect consensus model, then we are back to where evidence-
based medicine (EBM) started twenty years ago. EBM proponents then
demanded that clinical experts should step down as review authors
because of their notoriously unsystematic evaluations of the literature. In
this perspective, a high level of consensus may rather be a measure of
the opinions among stakeholders, than synonymous with best evidence.
On the other hand, we still struggle with the handling of quantitative data
to make trustworthy comparisons across interventions.
A systematic review of non-steroidal anti-inﬂammatory drugs (NSAID)
in knee osteoarthritis which we performed, can serve as an example
of the difﬁculties associated with quantitative data. We found that some
trials only recruited known responders to NSAID who had 49.4% higher
effect size compared to patients in trials which did not. The inﬂated
effect size in the subgroup of biased trials, led to an overall inﬂated
effect size by 24.3%. This fact hampers valid comparisons between
NSAID and other interventions. Because of the strict exclusion of co-
interventions in most NSAID-trials, there is also a lack of data for the effect
of NSAID in combination with potentially effective exercise therapy. There
are examples of trials with other interventions which do the opposite,
and recruit known non-responders in addition to allowing effective co-
interventions. Comparisons across interventions may then be ﬂawed.
Conclusions: There is still a way to go before we can be satisﬁed with
our methods for synthesizing best evidence. When a consensus-oriented
approach is selected, it seems important to balance guidelines developer
groups with involved stakeholders. If best evidence is sought from hard
quantitative data, more attention should probably be paid to differences
in patient selection criteria, intervention characteristics and allowed co-
interventions.
I-4 RESOURCES FOR FUTURE GUIDELINES & RESEARCH:
AN OARSI ‘TOOLBOX’ AND AN ‘EVIDENCE-BASED OA
RESEARCH DATABASE’ (EBOARD)
W. Zhang1, G. Nuki2. 1Nottingham University, Nottingham, UNITED
KINGDOM, 2University of Edinburgh, Edinburgh, UNITED KINGDOM
Purpose: More than 50 pharmacological, non-pharmacological and sur-
gical therapies are available for treating osteoarthritis (OA) [1] and
there are now 25 published guidelines for the management of OA.
The Osteoarthritis Research Society International (OARSI) has recently
published 25 recommendations for the management of hip and knee
OA [2]. However guidance for patients and clinicians on the order in which
such treatments, or combination of treatments, should be offered is much
less secure. While algorithms are frequently promulgated as simple aids
to guide physicians and patients through the welter of options, evidence
to support the use of one treatment prior to another is rarely available,
The clinical application of algorithms is also restricted by the need to tailor
treatment to the individual patient depending on the severity of symptoms,
the stage of disease, the presence of comorbidities, the risk of side effects
and the use of other drugs, etc.
An alternative approach which OARSI is developing is a toolbox con-
taining all effective treatment options. This is more ﬂexible to apply and
in many instances better supported by research evidence. It also has
the advantage that decisions to use one and/or another recommended
treatment is made by the users themselves, rather than by the guideline
developers.
The relevance and utility of treatment guidelines is also time limited by
the rapid accumulation of new research evidence. Risk-beneﬁt ratios for
some therapies currently recommended by OARSI have already changed
and some of the differences in the recommendations for the treatment of
OA contained in the NICE guidelines published in February 2008 [3] are
attributable to such new research evidence. So which guidelines should
one follow and how should one assess and weight the quality of evidence?
While one can criticise the OARSI guidelines for pooling results from all
RCTs regardless of quality, one must also be aware of potential bias
when different quality criteria are used for determining recommendations
for different modalities of therapy. It is, however, impossible to apply the
same quality criteria to all modalities of therapy unless all individual trials
are collected and characterised.
We therefore propose to develop an Evidence based OA Research
Database (eBOARD). This will be a comprehensive and coherent
database of well characterised trials of all modalities of treatment for
OA. In addition to containing details of patient demographics, disease
characteristics and treatments it will include quality assessments using
a single, standard instrument and measures of outcomes such as ES,
NNT, RR/OR and cost/QALY. The database will be updated annually with
the key messages and summary statistics for each therapy. We believe
that this database will be useful for (1) developing and updating treat-
ment guidelines; (2) answering speciﬁc clinical questions concerning the
efﬁcacy or side effects of any modality of therapy; undertaking evidence
based research, such as meta-analysis, sensitivity analysis, and cumula-
tive meta-analysis. It will also provide an unconstrained hypothesis-free
database of OA therapy that can be used to generate and test new
hypotheses.
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I-5 MOVING FROM GUIDELINES TO STANDARDS OF CARE
C. Kwoh. University of Pittsburgh, Pittsburgh, PA, USA
Purpose: Treatment guidelines are designed to assist clinical decision-
making by deﬁning a set of optimal patient care strategies. The best
treatment guidelines are evidence-based, but there are often limitations
in the availability of data from clinical trials to inform their development.
Guidelines are therefore frequently a combination of expert opinion and
the best available evidence.
What are the next steps after the development of treatment guidelines?
Ideally, guidelines also identify gaps in knowledge and areas where more
evidence would be helpful. Guidelines need to be disseminated to the
target audience of providers. Effective dissemination often requires a
multi-pronged approach.
The ultimate goal of treatment guidelines is to improve the quality of
care for a given condition through improved patient outcomes, enhanced
physician efﬁciency and/or greater health system productivity. Quality
indicators or performance standards are designed to deﬁne a minimally
acceptable level of care. Quality indicators may address a combination of
overuse, underuse or misuse of diagnostic and/or treatment modalities.
Quality indicators should be relevant, have scientiﬁc validity and be
feasible for implementation into clinical practice.
Methods: Quality indicators are used to assess the quality of care
delivered by providers, hospitals, health systems and/or other health care
organizations. Benchmarking can be used to summarize the performance
of a speciﬁc group of entities on a set of quality indicators to identify the
highest and lowest performing entities. Quality indicators can also be
used to identify/deﬁne/recognize the highest quality providers or health
systems. Risk adjustment may be needed to control for differences in
case-mix among providers or health systems.
Quality improvement is based on measurement. A performance measure
is a set of technical speciﬁcations that deﬁne how to calculate a “rate” for
a particular quality indicator. This rate is equivalent to the numerator, or
number of eligible patients who meet the quality indicator divided by the
denominator, or number of patients who meet inclusion criteria minus the
number of patients excluded due to medical, patient, or health system
reasons.
Results: The development of quality indicators is similar to the process
of developing treatment guidelines. A priority area is identiﬁed; a panel
of experts is convened; the available evidence is summarized through
a literature review; a draft set of measures is deﬁned; the expert panel
evaluates the draft set of measures; speciﬁcations are developed to deﬁne
the numerator of eligible patients who meet the quality indicator, the
denominator of patients who meet inclusion criteria, and potential reasons
for excluding patients from the denominator. The performance measure
undergoes ﬁeld-testing to assess feasibility.
Conclusions: Existing examples of quality indicators for knee and hip
osteoarthritis will be presented.
I-6 RISK STRATIFICATION FOR OA PROGRESSION
D.J. Hunter. New England Baptist Hospital, Boston, MA, USA
Purpose: The medial compartment of the knee is the most common site
of involvement in knee OA, and has been the subject of the most previous
studies in this context. Although many joint structures are affected in
OA, OA manifests prominently in the articular cartilage. Traditionally the
progression of knee OA has been assessed by measuring changes in
the width of the space between the medial femoral condyle and medial
tibial plateau on plain x-rays. More recently interest has grown in the
